Patricia Morgan, MD
Neurology · Hammond, LANPI 1174783070
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 920 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 11.1% — the pattern of someone who eats at a lot of different presentations.
Across 920 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$1K
- SK Life Science, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- Amgen$859
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$250%
- Food & beverage$16,11899%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYEPTI$125
How this compares
$16,254 in reported general payments places this provider in the 80th percentile of 225 neurology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $375,383 |
| Nurtec OdtRimegepant Sulfate | 160 | $225,076 |
| Austedo XrDeutetrabenazine | 26 | $195,530 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 15 | $121,087 |
| RexultiBrexpiprazole | 64 | $109,821 |
| Emgality PenGalcanezumab-Gnlm | 129 | $104,193 |
| Teriflunomide | 21 | $87,773 |
| QuliptaAtogepant | 63 | $74,457 |
| Dimethyl Fumarate | 17 | $70,367 |
| UbrelvyUbrogepant | 57 | $66,108 |
| Aimovig AutoinjectorErenumab-Aooe | 61 | $52,937 |
| VraylarCariprazine Hcl | 33 | $52,712 |
| BotoxOnabotulinumtoxina | 39 | $51,648 |
| BriviactBrivaracetam | 18 | $51,015 |
| XcopriCenobamate | 36 | $39,333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $166 | $375,38317 claims |
| AbbVieQulipta, Ubrelvy, Vraylar, Botox, Namzaric | $1,798 | $258,466205 claims |
| PfizerNurtec Odt, Eliquis | $855 | $234,856173 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,143 | $195,53026 claims |
| Grifols USA, LLCGamunex-C | $59 | $121,08715 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $190 | $109,82164 claims |
| UCB, Inc.Briviact, Nayzilam, Neupro | $1,446 | $88,38953 claims |
| SK Life Science, Inc.Xcopri | $1,160 | $39,33336 claims |
| MDD US Operations, LLCGocovri | $236 | $31,27218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $171 | $13,30836 claims |
| Lilly USA, LLCCymbalta | $569 | $3,85114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 neurology providers in Louisiana.
Other neurology in Hammond
- Meghan HarrisShreveport$553K
- Kevin CallerameBaton Rouge$420K
- Gerald CaleganBaton Rouge$400K
- Maria Carmen WilsonCovington$295K
- John EnglandNew Orleans$268K
- Ariel Antezana AntezanaAlexandria$253K
- Brian CopelandNew Orleans$211K
- Bridget BagertNew Orleans$198K
- Carol RedillasChalmette$192K
- Erik BurtonShreveport$154K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.